<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925106</url>
  </required_header>
  <id_info>
    <org_study_id>A3191355</org_study_id>
    <nct_id>NCT00925106</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Of Celecoxib Test Formulations</brief_title>
  <official_title>A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Celecoxib Formulations D1, D2 And D3 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected
      to provide more favorable bioavailability characteristics than the present commercial
      formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf, AUCt, Cmax</measure>
    <time_frame>1.5 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual inspection of median plasma concentration versus time profiles resulting from each formulation</measure>
    <time_frame>1.5 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax, half-life</measure>
    <time_frame>1.5 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events, laboratory tests, vital signs</measure>
    <time_frame>1.5 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Celebrex capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test formulation D1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test formulation D2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test formulation D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex capsule</intervention_name>
    <description>Single dose 200 mg commercial Celebrex capsule</description>
    <arm_group_label>Celebrex capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation D1</intervention_name>
    <description>Single dose 150 mg celecoxib as formulation D1</description>
    <arm_group_label>D1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation D2</intervention_name>
    <description>Single dose 150 mg celecoxib as formulation D2</description>
    <arm_group_label>D2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation D3</intervention_name>
    <description>Single dose 150 mg celecoxib as formulation D3</description>
    <arm_group_label>D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteers

          -  Body weight BMI 17.5-30.5

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
             allergic disease

          -  Positive urine drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191355&amp;StudyName=Pharmacokinetics%20Of%20Celecoxib%20Test%20Formulations</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <last_update_submitted>August 19, 2010</last_update_submitted>
  <last_update_submitted_qc>August 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Bioavailability, pharmacokinetics, celecoxib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

